NfL Biomarker Assay Kit for Neurological Research

A universal biomarker for neuronal injury across neurological disorders

Neurofilament Light Chain (NfL) is a blood-based biomarker serving as a general indicator of axonal damage and neuronal injury across various neurological conditions, including Alzheimer’s disease (AD).

NfL strongly correlates with neurodegenerative processes and amyloid pathology in AD, as measured by positron emission tomography (PET) and cerebrospinal fluid (CSF) analysis. It also acts as a broad marker of neuronal injury in conditions such as stroke, traumatic brain injury (TBI), and multiple sclerosis (MS).

Unparalleled Precision with SPEAR UltraDetect Nf-L

The Spear UltraDetect Nf-L demonstrates Unparalleled Sensitivity and Precision, measuring all healthy samples above fLLOQ with extremely low intra-plate and inter-plate CVs. Researchers leveraging Nf-L desire sensitivity and precision – critical immunoassay performance metrics that enable detection of small changes in multi-year longitudinal studies while Clinical trial researcher desire the same performance benefits for applications in enrichment and pharmacodynamic studies.

Confirming this performance with clinical samples – including healthy controls and disease patient samples, the SPEAR UltraDetect Nf-L assay quantified 100% of patient samples was able to achieve a mean CV% of 3.2%.

SPEAR UltraDetect Nf-L assay precision
[1 µL diluted sample]

SPEAR UltraDetect Nf-L sample quantifiability (>LLOQ)
[1 µL diluted sample]

Assay Specifications

MRD	4X
Diluted Sample Volume	1µL
Raw Sample Volume to Machine	10µL
LOD (pg/mL)	0.024
fLLOQ (pg/mL)	0.500
Spike-recovery (% recovery)	95%
Linearity (% recovery)	97%
Intra-plate CV (AVG%)	3.2%
Inter-plate CV (AVG%)	5.4%
EDTA Plasma Quantifiability	100%

Supporting Research on Neurological and Neurodegenerative Diseases

Neurofilament light chain (NfL) is a structural intermediate filament protein, part of a triplet system that includes neurofilament medium (125 kDa) and neurofilament heavy (200 kDa) chains. NfL, with a molecular weight of approximately 68 kDa, is the most abundant and soluble of these proteins and is expressed in neurons, particularly within large-caliber axons.

When axonal damage occurs—as in Alzheimer’s disease, amyotropic lateral sclerosis (ALS), traumatic brain injury (TBI), or multiple sclerosis (MS)—NfL is released into biofluids, including cerebrospinal fluid (CSF) and, to a lesser concentration, in blood. While CSF analysis remains a common method for measuring NfL, blood-based detection offers a less invasive, more scalable option for longitudinal and population-level research.

The SPEAR UltraDetect™ Nf-L biomarker assay kit is specifically designed to support plasma- and serum-based studies of:

Progressive neurodegenerative diseases
Neurological disease onset and progression tracking
Therapeutic development targeting axonal protection
Biomarker validation and stratification strategies across study cohorts

Recommended for Research Across Sample Types and Settings

This NfL biomarker assay kit is intended for Research Use Only (RUO) and is optimized for plasma and serum samples. With minimal sample input and compatibility with qPCR instrumentation, it provides the flexibility to meet the demands of both high-throughput screening and targeted biomarker validation studies. The assay’s performance characteristics make it especially well-suited for:

Clinical research programs focused on axonal injury and repair
Longitudinal monitoring of neurological disease progression
Early-phase intervention studies in ALS, MS, or mild cognitive impairment
Multi-target analysis strategy, including variants of phosphorylated tau and GFAP

Designed for Performance Without Operational Burden

The SPEAR platform was engineered to remove the complexity often associated with ultrasensitive protein detection. Unlike conventional or digital ELISA technologies, which employ a heterogeneous workflow dependent on solid-surface binding, or methods requiring proprietary readout instrumentation, SPEAR’s homogeneous, wash-free format simplifies every step of the workflow.

Its dual-authentication mechanism ensures every analyte signal is verified twice—sharpening resolution even when working at the lower limits of detection. Combined with attomolar sensitivity and low CVs, SPEAR delivers reproducible results that support discovery, validation, translational, and clinical applications alike.